Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 743-745

  Reid, Robin ^a   Bennett, John M ^a   Becker, Michael ^a   Chen, Yuhchyau ^a   Milner, Laurie ^a   Phillips II, Gordon L ^a   Liesveld, Jane ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOCAPROIC ACID; BUSULFAN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEFERASIROX; ELTROMBOPAG; ERYTHROPOIETIN; FLUDARABINE; FOSCARNET; HYDROXYUREA; IDARUBICIN; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MEGADOSE; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DUPLICATION; GRAFT VERSUS HOST REACTION; HOSPICE CARE; HUMAN; IRON OVERLOAD; LETTER; MEDICAL HISTORY; MEGAKARYOCYTE; MUCOSAL BLEEDING; PRIORITY JOURNAL; PUVA; REDUCED INTENSITY CONDITIONING; SPLENOMEGALY; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VIRUS REACTIVATION; WHOLE BODY RADIATION;

ADULT; BENZOIC ACIDS; FATAL OUTCOME; FEMALE; HUMANS; HYDRAZINES; MIDDLE AGED; PLATELET COUNT; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84862530848     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23225     Document Type: Letter

References (10)

1. Kuzmina Z, Eder S, Bohm A, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: Results of a prospective study. Leukemia 2012; 26: 746-756.
2. Bolwell B, Pohlman B, Sobecks R, et al. Prognostic importance of platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant 2004; 33: 419-423.
3. Pulanic D, Lozier JN, andPavletic S. Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Bone Marrow Transplant 2009; 44: 393-403.
4. Zaja F, Geromin A, Patriarca F, et al. Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. Am J Hematol 2011; 86: 790-792.
5. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357: 2237-2247.
6. McHutchinson JG, Dusheiko G, Shiffman ML, et al. TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated hepatitis C. N Engl J Med 2007; 29: 2227-2236.
7. LI J, Yang C, Xia Y, Bertino A, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
8. Nakamae H, Storer B, Sandmaier BM, et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: Impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011; 96: 1838-1845.
9. Will B, Kawahara M, Luciano JP, Bruns I. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009; 114: 3899-3908.
10. Calmettes C, Vigouroux S, Tabrizi R, Milpied N. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT. Bone Marrow Transplant 2011; 45: 1587-1589.